VU-0152100
A detailed overview of the experimental drug VU-0152100
VU-0152100[edit | edit source]
VU-0152100 is an experimental compound that has been studied for its potential effects on the central nervous system. It is primarily known for its role as a selective positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4). This compound has been of interest in the field of neuroscience due to its potential therapeutic applications in neurological disorders.
Mechanism of Action[edit | edit source]
VU-0152100 functions by modulating the activity of mGluR4, a receptor that is part of the glutamate receptor family. Glutamate is the primary excitatory neurotransmitter in the brain, and its receptors are involved in a wide range of physiological processes. By acting as a positive allosteric modulator, VU-0152100 enhances the receptor's response to glutamate, potentially leading to increased receptor activity without directly activating the receptor itself.
Potential Therapeutic Applications[edit | edit source]
Research into VU-0152100 has suggested several potential therapeutic applications, particularly in the treatment of Parkinson's disease and other neurodegenerative disorders. The modulation of mGluR4 has been shown to have neuroprotective effects, which could be beneficial in slowing the progression of these diseases.
Parkinson's Disease[edit | edit source]
In models of Parkinson's disease, VU-0152100 has demonstrated the ability to reduce motor deficits and protect dopaminergic neurons. This suggests that mGluR4 modulation could be a viable strategy for developing new treatments for Parkinson's disease.
Other Neurological Disorders[edit | edit source]
Beyond Parkinson's disease, VU-0152100 is being investigated for its potential in treating other conditions such as anxiety disorders, schizophrenia, and epilepsy. The modulation of glutamatergic signaling pathways is a promising area of research for these disorders.
Research and Development[edit | edit source]
The development of VU-0152100 is still in the experimental stages, with ongoing studies to better understand its pharmacokinetics, safety profile, and efficacy in various models. Researchers are also exploring the compound's potential interactions with other neurotransmitter systems and its long-term effects on brain function.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
